In Vivo Pharmacokinetic Study of Remdesivir Dry Powder for Inhalation in Hamsters
Preprint
Abstract
Remdesivir dry powder for inhalation was previously developed using thin film freezing (TFF). A single-dose 24-hour pharmacokinetic study in hamsters, a small animal model for SARS-CoV-2, demonstrated that pulmonary delivery of TFF remdesivir can achieve plasma remdesivir and GS-441524 levels higher than the reported EC 50 s of both remdesivir and GS-441524 (in human epithelial cells) over 20 hours. The half-life of GS-4412524 following dry powder insufflation was about 7 hours, suggesting the dosing regimen would be twice daily administration. Although the remdesivir-Captisol ® (80/20 w/w) formulation showed faster and greater absorption of remdesivir and GS-4412524 in the lung, remdesivir-leucine (80/20 w/w) exhibited a greater C max with shorter T max and lower AUC of GS-441524, indicating lower total drug exposure is required to achieve a high effective concentration against SAR-CoV-2. In conclusion, remdesivir dry powder for inhalation would be a promising alternative dosage form for the treatment of COVID-19 disease.Keywords
All Related Versions
- Published version: International Journal of Pharmaceutics: X, 3, 100073.
This publication has 27 references indexed in Scilit:
- The ProTide Prodrug Technology: Where Next?ACS Medicinal Chemistry Letters, 2018
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility–permeability interplayEuropean Journal of Pharmaceutical Sciences, 2015
- Naive Pooled–Data Approach for Pharmacokinetic Studies in Pediatrics With a Very Small Sample SizeAmerican Journal of Therapeutics, 2014
- Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to miceEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solutionEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Improved Aqueous Solubility of Crystalline Astaxanthin (3,3′‐dihydroxy‐β, β‐carotene‐4,4′‐dione) by Captisol® (Sulfobutyl Ether β‐Cyclodextrin)Journal of Pharmaceutical Sciences, 2003
- Sparse-Sampling Optimal Designs in Pharmacokinetics and ToxicokineticsDrug Information Journal, 1995